Breast cancer: new aspects of adjuvant hormonal therapy

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study.

ESMO open·2026

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

A Nomogram to Estimate Locoregional Recurrence-Free Survival for Women With T1-2 N0 Breast Cancer Managed With or Without Postmastectomy Radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025

The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.

ESMO open·2025

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Thymic Radiation is Associated with Worse Outcomes in Patients with NSCLC.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Immune Cell Engager Therapy for Brain Cancer.

Neuro-oncology·2026

Gut microbiota-mediated dietary lignans metabolism drives accumulation of N,N-dimethylsphingosine and sensitizes triple-negative breast cancer to paclitaxel.

Food & function·2026

Ocular Microcystic Adnexal Carcinoma With High-Grade Features: A Case Report With Orbital Exenteration.

International journal of surgical pathology·2026

Effect of photobiomodulation therapy on regulating reparative processes of chronic wounds at the inflammation stage.

Biomedica : revista del Instituto Nacional de Salud·2026

Doxorubicin and 4-Hydroperoxycyclophosphamide Alter Mitochondrial Dynamics and miR-34 Expression in Spermatogonia and Spermatocytes In Vitro.

Basic & clinical pharmacology & toxicology·2026

Neurotoxicity and cognitive outcomes in modern therapies for primary central nervous system lymphoma.

Current opinion in oncology·2026

Related Experiment Videos

Breast cancer: new aspects of adjuvant hormonal therapy

Related Concept Videos

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study.

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

A Nomogram to Estimate Locoregional Recurrence-Free Survival for Women With T1-2 N0 Breast Cancer Managed With or Without Postmastectomy Radiotherapy.

The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).

Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.

Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.

Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.

Thymic Radiation is Associated with Worse Outcomes in Patients with NSCLC.

Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.

Immune Cell Engager Therapy for Brain Cancer.

Gut microbiota-mediated dietary lignans metabolism drives accumulation of N,N-dimethylsphingosine and sensitizes triple-negative breast cancer to paclitaxel.

Ocular Microcystic Adnexal Carcinoma With High-Grade Features: A Case Report With Orbital Exenteration.

Effect of photobiomodulation therapy on regulating reparative processes of chronic wounds at the inflammation stage.

Doxorubicin and 4-Hydroperoxycyclophosphamide Alter Mitochondrial Dynamics and miR-34 Expression in Spermatogonia and Spermatocytes In Vitro.

Neurotoxicity and cognitive outcomes in modern therapies for primary central nervous system lymphoma.

Related Experiment Videos

Breast cancer: new aspects of adjuvant hormonal therapy

Related Concept Videos

Related Articles